Lactose-Conjugated PLGA Nanoparticles for Enhanced Delivery of Rifampicin to the Lung for Effective Treatment of Pulmonary Tuberculosis

References

1. 1.↵
   1. Deol P.,
   2. Khuller G. K.

   Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys, Acta. 1997, 1334 (2–3), 161–172.

   OpenUrlPubMed
2. 2.↵
   1. Teo S. K.

   Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int. J. Tuberc. Lung Dis. 1999, 3 (2), 126–132.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Girgling D. J.

   The hepatic toxicity of antituberculosis regimens containing isoniazi rifampicin and pyrazinamide. Tubercle 1978, 59, 13–32.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Zierski M.,
   2. Bek E.

   Side effects of drug regimens used in short course chemotherapy for pulmonary tuberculosis: a controlled study. Tubercle 1980, 61, 41–49.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Barrow E. L. W.,
   2. Winchester G. A.,
   3. Staas J. K.,
   4. Quenelled D. C.,
   5. Barrow W. W.

   Use of microsphere technology for targeted delivery of rifampin to mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 1998, 42 (10), 2682–2689.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Dutt M.,
   2. Khuller G. K.

   Liposomes and PLG microparticles as sustained release antitubercular drug carriers—an in-vitro in-vivo study. Int. J. Antimicrob. Agents 2001, 18 (3), 245–252.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Sharma R.,
   2. Saxena D.,
   3. Dwivedi A. K.,
   4. Misra A.

   Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18 (10), 1405–1410.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Suarez S.,
   2. O'Hara P.,
   3. Kazantseva M.,
   4. Newcomer C. E.,
   5. Hopfer R.,
   6. McMurray D. N.

   Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 2001, 48 (3), 431–434.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Denkbas E. B.,
   2. Kaitian X.,
   3. Tuncel A.,
   4. Piskin E.

   Rifampicin-carrying poly(d,l-lactide) microspheres: loading and release. J. Biomater. Sci. Polym. Ed. 1995, 6 (9), 815–825.

   OpenUrlPubMed
10. 10.↵
    1. Pandey R.,
    2. Sharma A.,
    3. Zahoor A.,
    4. Sharma S.,
    5. Khuller G. K.,
    6. Prasad B.

    Poly (d,l-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 2003, 52 (6), 981–986.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Pandey R.,
    2. Sharma S.,
    3. Khuller G. K.

    Oral solid lipid nanoparticles based antitubercular chemotherapy. Tuberculosis 2005, 85 (5–6), 415–420.

    OpenUrlPubMed
12. 12.↵
    1. Jain R. A.

    The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) devices. Biomaterials 2000, 21 (23), 2475–2490.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Soppimath K. S.,
    2. Aminabhari T. M.,
    3. Kulkarni A. R.,
    4. Rudzinski W. E.

    Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 2001, 70 (1–2), 1–20.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Knight C. G.

    Liposomes from Physical Structure to Therapeutic Applications. Elsevier: Amsterdam, 1981; pp 129–132.
15. 15.↵
    1. Ogawa Y.,
    2. Okada H.,
    3. Heya T.,
    4. Shimamoto T. J.

    Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmacol. 1989, 41 (7), 439–444.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Derrien D.,
    2. Midous P.,
    3. Petit C.

    Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj. J. 1989, 6 (2), 241–255.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Klink D. T.,
    2. Glick M. C.,
    3. Scanlin T. F.

    Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose. Glycoconj. J. 2001, 18 (9), 731–740.

    OpenUrlPubMed
18. 18.↵
    1. Kollen W. J. W.,
    2. Schembri F. M.,
    3. Gerwig G. J.,
    4. Vliegenthart J. F. G.,
    5. Glick M. C.,
    6. Scanlin T. F.

    Enhanced efficiency of lactosylated poly-L-lysine-mediated gene transfer into cystic fibrosis airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 1999, 20 (5), 1081–1086.

    OpenUrlPubMed
19. 19.↵
    1. Yoon J. J.,
    2. Nam Y. S.,
    3. Kim J. H.,
    4. Park T. G.

    ; Surface immobilization of galactose onto aliphatic biodegradable polymers for hepatocyte culture. Biotechnol. Bioeng. 2002, 78 (1), 1–10.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Fessi H.,
    2. Puisieux F.,
    3. Devissaguet J. P.,
    4. Ammoury N.,
    5. Benita S.

    Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55 (1), R1–R4.

    OpenUrlCrossRefWeb of Science
21. 21.↵
    1. Musumeci T.,
    2. Ventura C. A.,
    3. Giannone I.,
    4. Ruozi B.,
    5. Montenegro L.,
    6. Pignatello R.,
    7. Puglisi G.

    PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 2006, 325 (1–2), 172–179.

    OpenUrlPubMed
22. 22.↵
    1. Pandey R.,
    2. Khuller G. K.

    Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J. Antimicro. Chemother. 2006, 57 (6), 1146–1152.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Gupta Y.,
    2. Soni V.,
    3. Chourasia M. K.,
    4. Jain A.,
    5. Khare P.,
    6. Jain S. K.

    Targeted drug delivery to the brain via transferrin coupled liposomes. Drug Deliv. Tech. 2005, 5, 66–71.

    OpenUrl
24. 24.↵
    1. Chan K.

    Rifampicin concentration in cerebrospinal fluid and plasma of the rabbit by high performance liquid chromatography. Methods Find. Exp. Clin. Pharmacol. 1986, 8 (12), 721–726.

    OpenUrlPubMed
25. 25.↵
    1. Gupta Y.,
    2. Jain A.,
    3. Jain S. K.

    Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 2007, 59 (7), 1–6.

    OpenUrlWeb of Science
26. 26.↵
    1. Choi S. W.,
    2. Kwon H. Y.,
    3. Kim W. S.,
    4. Kim J. H.

    Thermodynamic parameters on poly(d,l-lactide-co-glycolide) particle size in emulsification diffusion process. Colloids Surf. Physicochem. Eng. 2002, 201 (1–3), 283–289.

    OpenUrl
27. 27.↵
    1. Garderton D.,
    2. Jones T.

    1. Holland S. J.,
    2. Tighe B. J.

    Biodegradable Polymers. In Advanced Pharmaceutical Sciences; Garderton D., Jones T. Eds.; Academic Press: New York, 1992; Vol. 6; pp 101–164.

    OpenUrl
28. 28.↵
    1. Makino K.,
    2. Nakajima T.,
    3. Shikamura M.,
    4. Ito F.,
    5. Ando S.,
    6. Kochi C.,
    7. Inagawa H.,
    8. Soma G.,
    9. Terada H.

    Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. B. Biointerfaces 2004, 36 (1), 35–42.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Ito F.,
    2. Makino K.

    Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres. Colloids Surf. B. Biointerfaces 2004, 39 (1–2), 17–21.

    OpenUrlPubMed
30. 30.↵
    1. Gupta Y.,
    2. Jain A.,
    3. Jain P.,
    4. Jain S. K.

    Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumour cells. J. Drug Target 2007, 15 (3), 231–240.

    OpenUrlCrossRefPubMed